Boston Scientific Corp. stock (US10117L1017): Shares slide amid valuation debate

Boston Scientific Corp. stock has fallen sharply in recent sessions, trading around the mid?$50s and sparking fresh debate over whether the medical device maker is undervalued.

Boston Scientific Corp. shares have pulled back in the past week, with the stock trading near $54 on the New York Stock Exchange as of early May 2026, according to market data from Kraken and other platforms.Kraken as of May 11, 2026 The move comes after a broader selloff in the stock, which has shed roughly 40% year?to?date, according to valuation?oriented research sites that track the company.Simply Wall St as of May 2026 Despite the decline, several valuation models and analyst surveys continue to rate Boston Scientific as undervalued relative to their intrinsic?value estimates and consensus price targets.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Boston Scientific Corporation
• Sector/industry: Medical devices and healthcare technology
• Headquarters/country: United States
• Core markets: United States, Europe, Asia?Pacific and other developed markets
• Key revenue drivers: Interventional cardiology, endoscopy, urology, neuromodulation and peripheral interventions
• Home exchange/listing venue: New York Stock Exchange (ticker: BSX)
• Trading currency: U.S. dollar

Boston Scientific Corp.: core business model

Boston Scientific Corp. is a global developer, manufacturer and marketer of minimally invasive medical devices used across a range of specialties, including cardiology, endoscopy, urology, neuromodulation and peripheral vascular interventions.Boston Scientific corporate site The company’s products are designed to help physicians diagnose and treat conditions such as coronary artery disease, atrial fibrillation, gastrointestinal disorders, kidney stones, chronic pain and movement disorders, often as alternatives to more invasive surgery. Its business model centers on recurring revenue from consumable devices, capital equipment and service contracts, supported by a global sales and clinical?support infrastructure.

For US investors, Boston Scientific offers exposure to long?term structural trends in healthcare, including an aging population, rising prevalence of chronic diseases and a shift toward less invasive procedures that can reduce hospital stays and recovery times.Boston Scientific corporate site The company’s US operations remain a core profit center, with a large installed base of devices and strong relationships with hospitals, ambulatory surgery centers and physician groups. At the same time, Boston Scientific continues to expand in emerging markets, where demand for advanced medical technology is growing but penetration remains relatively low.

Main revenue and product drivers for Boston Scientific Corp.

Boston Scientific’s revenue is broadly split across several key franchises, each anchored by flagship product lines and supported by ongoing innovation and clinical data.Boston Scientific corporate site In interventional cardiology, the company markets drug?eluting stents, balloon catheters and other devices used in percutaneous coronary interventions, competing with larger rivals such as Abbott and Medtronic. In endoscopy, Boston Scientific offers a portfolio of scopes, accessories and therapeutic devices for gastrointestinal and pulmonary procedures, including technologies for early?stage cancer detection and removal.

Another important growth area is neuromodulation, where Boston Scientific sells implantable devices for chronic pain and movement disorders, as well as related leads and programmers.Boston Scientific corporate site The company also derives significant revenue from urology and pelvic health products, such as devices for treating benign prostatic hyperplasia and urinary incontinence, and from peripheral interventions used to treat vascular disease in the legs and other non?coronary vessels. Across these franchises, Boston Scientific emphasizes clinical evidence, regulatory approvals and reimbursement support to drive adoption and sustain pricing power.

Why Boston Scientific Corp. matters for US investors

For US retail investors, Boston Scientific represents a diversified medical?device play with a strong domestic footprint and meaningful international exposure.Boston Scientific corporate site The company’s listing on the NYSE and its inclusion in major healthcare and large?cap indices make it accessible to a broad range of equity portfolios, from growth?oriented funds to dividend?aware strategies. Its business is closely tied to US healthcare spending, Medicare and Medicaid reimbursement policies, and the pace of innovation in minimally invasive therapies, all of which can influence long?term earnings trajectories.

Recent price action has highlighted the stock’s sensitivity to macroeconomic factors, interest?rate expectations and sector?specific news, such as regulatory developments or clinical?trial results.GuruFocus as of May 8, 2026 At the same time, valuation?oriented analyses and analyst surveys suggest that the current share price may not fully reflect the company’s underlying fundamentals or growth potential, which can create opportunities for investors comfortable with the sector’s inherent volatility and regulatory risks.

Conclusion

Boston Scientific Corp. remains a leading global medical?device company with a diversified portfolio of minimally invasive technologies and a strong presence in the US healthcare market.Boston Scientific corporate site The stock’s recent decline has pushed shares into a range where several valuation models and analyst surveys indicate potential undervaluation, even as the company continues to navigate competitive pressures, regulatory scrutiny and macroeconomic uncertainty.GuruFocus as of May 8, 2026Marketscreener as of May 2026

For US investors, Boston Scientific offers exposure to long?term healthcare trends but also carries typical medical?device risks, including product?liability claims, reimbursement changes and the need for continuous innovation.Boston Scientific corporate site The current valuation debate underscores the importance of understanding both the company’s fundamentals and the broader sector environment before making any investment decision. This article does not constitute investment advice; investors should conduct their own research and consider their risk tolerance and time horizon.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.